Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Spectrum Pharmaceuticals, Inc.    SPPI

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Spectrum Pharmaceuticals, Inc. : Hagens Berman Notifies Spectrum Pharmaceuticals Investors of Pending Class-Action Lawsuit and May 13, 2013, Lead Plaintiff Deadline

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/22/2013 | 02:35pm CEST

Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, is investigating Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) ("Spectrum" or "The Company") following the filing of a class-action lawsuit on behalf of investors. The firm encourages those who have suffered losses to contact Hagens Berman Partner Reed Kathrein, who is leading the Firm's investigation, by emailing SPPI@hbsslaw.com.

A class-action lawsuit filed in U.S. District Court identifies a class of Spectrum investors who purchased stock in the company between August 8, 2012, and March 12, 2013, inclusive (the "class period"). Those who suffered significant losses and wish to move to be a lead plaintiff may also contact the firm by calling (510) 725-3000.

Investors who wish to serve as lead plaintiff in the case must move the court no later than May 13, 2013. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

On March 12, 2013, Spectrum disclosed to investors that it would significantly lower its 2013 revenue guidance on concerns that sales of its drug FUSILEV would be lower than expected. Following the disclosure, Spectrum's stock price fell dramatically, from a close of $12.43 per share on March 12 to a close of $7.79 per share on March 13. The stock has continued to trade at or around $7.00 since the disclosure.

Hagens Berman's investigation centers around whether Spectrum knew and failed to disclose to investors concerns about the sales of FUSILEV.

"We are concerned that Spectrum knew that generic competition would substantially impact the company's revenues and failed to disclose these concerns to investors," said Mr. Kathrein. "We believe the company's alleged failure to come clean with investors about these issues may have artificially inflated the stock price, resulting in very significant investor losses."

Hagens Berman reminds whistleblowers with inside information that rewards may be available to individuals who report information leading to a successful enforcement action by the Securities and Exchange Commission. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.

More information about this investigation is available at http://www.hb-securities.com/investigations/SPPI.

About Hagens Berman

Hagens Berman Sobol Shapiro LLP is an investor-rights class-action law firm with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the law firm and its successes can be found at www.hbsslaw.com. The Firm's securities law blog is at http://www.meaningfuldisclosure.com.

Firmani + Associates
Mark Firmani, 206-443-9357
Mark@firmani.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SPECTRUM PHARMACEUTICALS,
08/18 SPECTRUM PHARMACEUTICALS : (SPPI) Initiates Phase II Study for Cancer Drug
08/17 SPECTRUM PHARMACEUTICALS : to Present Corporate Update at the 2017 Southern Cali..
08/16 CASI PHARMACEUTICALS : Reports Second Quarter 2017 Financial Results
08/15 SPECTRUM PHARMACEUTICALS : Announces Initiation of the Registrational Phase 3 Tr..
08/14 SPECTRUM PHARMACEUTICALS : Announces Initiation of the Registrational Phase 3 Tr..
08/04 SPECTRUM PHARMACEUTICALS, INC. (NASD : SPPI) Files An 8-K Entry into a Material ..
08/04 SPECTRUM PHARMACEUTICALS INC : Entry into a Material Definitive Agreement (form ..
08/03 SPECTRUM PHARMACEUTICALS : Reports Second Quarter 2017 Financial Results and Pip..
08/03 SPECTRUM PHARMACEUTICALS, INC. (NASD : SPPI) Files An 8-K Results of Operations ..
08/03 SPECTRUM PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fi..
More news
News from SeekingAlpha
08/16 Premarket analyst action - healthcare
08/14 Spectrum's additional late-stage study of apaziquone in bladder cancer underw..
08/08 What To Expect After Spectrum Pharmaceuticals' Robust Earnings
08/04 Spectrum Pharmaceuticals' (SPPI) CEO Rajesh Shrotriya on Q2 2017 Results - Ea..
08/04 Spectrum Pharma Q2 beat propels shares, up 21%
Financials ($)
Sales 2017 133 M
EBIT 2017 -75,8 M
Net income 2017 -83,4 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 5,96x
Capi. / Sales 2018 5,93x
Capitalization 794 M
Chart SPECTRUM PHARMACEUTICALS,
Duration : Period :
Spectrum Pharmaceuticals,  Technical Analysis Chart | SPPI | US84763A1088 | 4-Traders
Technical analysis trends SPECTRUM PHARMACEUTICALS,
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 11,5 $
Spread / Average Target 22%
EPS Revisions
Managers
NameTitle
Rajesh C. Shrotriya Chairman & Chief Executive Officer
Joseph W. Turgeon President & Chief Operating Officer
Kurt A. Gustafson Chief Financial Officer & Executive Vice President
Stuart Mitchell Krassner Independent Non-Employee Director
Luigi Lenaz Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SPECTRUM PHARMACEUTICALS, INC.112.19%794
INCYTE CORPORATION20.86%24 929
QUINTILES IMS HOLDINGS INC20.38%19 823
LONZA GROUP40.29%17 682
CELLTRION, INC.--.--%11 804
ALKERMES PLC-8.38%7 821